#apaperaday
Prof. Annemieke Aartsma-Rus is taking on a challenge by reading and commenting on a paper a day. She shares her insights, findings and thoughts via her @oligogirl Twitter account. See below the overview of January 2024.
***
Prof. Aartsma-Rus reads and comments on the paper titled: Fat embolism syndrome in Duchenne muscular dystrophy: Report on a novel case and systematic literature review
Today's pick is from European Journal of Paediatric Neurology by Specht et al on a Duchenne patient with fat embolism after surgery doi 10.1016/j.ejpn.2023.11.012
Fat embolisms can occur after a long bone fracture where bone marrow content accesses the circulation. This can lead to respiratory distress and neurological problems when the fragments get stuck in lung and brain capillaries.
Usually symptoms occur 1-3 days after a fracture. They can be mild and transient or lead to death. Duchenne patients are at risk for fractures and thus also for fat embolisms. Authors here present a case report of a 13 year old patient who underwent orthopedic surgery.
The patient had never been on steroids and was wheelchair dependent since 9 years. After surgery he first recovered well and then went into respiratory distress requiring ventilation after 24 hours. 9 days post surgery he was weaned off ventilation. Analysis revealed the patient had experienced fractures of both femoral during surgery. This resulted in fat embolisms in the lung but also the brain. Authors detected white matter injury. The patient has minimal consciousness 5 months post surgery.
Authors performed a literature review finding 11 cases of fat embolism syndrome in Duchenne patients after a fracture. This was usually due to a fall from the wheelchair or during transfer and usually of the femur. Most of the cases were on steroids.
Respiratory problems and tachycardia were most common symptoms and most patients needed ventilation. Some patients also experienced confusion, lethargy and seizures. 29% of patients died due to the embolism and 54% fully recovered.
Prof. Dr. Annemieke Aartsma-Rus is a professor of Translational Genetics at the Department of Human Genetics of the Leiden University Medical Center. Since 2013 she has a visiting professorship at the Institute of Genetic Medicine of Newcastle University (UK).
Her work currently focuses on developing antisense-mediated exon skipping as a therapy for Duchenne muscular dystrophy. In addition, in collaborative efforts she aims to bridge the gap between different stakeholders (patients, academics, regulators and industry) involved in drug development for rare diseases.
In 2013 she was elected a member of the junior section of the Dutch Royal Academy of Sciences (KNAW), which consists of what are considered the top 50 scientists in the Netherlands under 45. From 2015 to 2022, she was selected as the most influential scientist in Duchenne muscular dystrophy by Expertscape.